P/E ratio for Glenmark Pharmaceuticals (GLENMARK.NS)
P/E ratio as of April 2024 (TTM): 113
According to Glenmark Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 113.188. At the end of 2022 the company had a P/E ratio of 13.6.
P/E ratio history for Glenmark Pharmaceuticals from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 13.6 | -7.11% |
| 2021 | 14.6 | 0.46% |
| 2020 | 14.6 | 6.51% |
| 2019 | 13.7 | -36.1% |
| 2018 | 21.4 | -17.07% |
| 2017 | 25.8 | 7.01% |
| 2016 | 24.1 | -42.72% |
| 2015 | 42.1 | 2.32% |
| 2014 | 41.1 | 90.87% |
| 2013 | 21.5 | -9.92% |
| 2012 | 23.9 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.